Table I.

Cytokine production of TCR-transduced PBL;a

Responder CellsStimulators (pg/ml IFN-γ released)
T2 aloneT2 + FluT2 + MART-1T2 + gp100 (209)T2 + gp100 (209-2M)
Patient 1
No vector7.5 (3.5)10 (0)12.5 (10.6)00
YFP28.8 (7.5)106 (100)62.5 (15.5)10 (10)13.8 (7.5)
APB86.3 (15.5)104 (17)136 (35)78,525 (5,610)204,700 (12,757)
BIA47.5 (19.4)52.5 (34.8)78.8 (14.9)58,800 (24,528)158,200 (109,419)
R6C1200041,390 (6,820)67,040 (9,010)
Stimulators (pg/ml GM-CSF released)
Patient 2
No vector3,875 (1,732)4,000 (565)3,400 (989)4,275 (1,166)5,350 (424)
YFP4,750 (1,750)6,550 (1,000)6,750 (1,933)5,025 (1,485)6,764 (757)
APB8,000 (1,156)7,188 (826)7,613 (1,780)30,438 (3,996)46,850 (3,513)
BIA6,025 (2,514)5,663 (1,251)5,688 (1,083)33,763 (9,080)49,113 (4,655)
TIL5,500 (919)1,900 (1,060)45,550 (9,687)35,200 (4,808)51,375 (1,450)
  • ;a Cytokine secretion of TCR vector-transduced PBL (responders) was exposed to T2 cells (stimulators) pulsed with HLA-A2-specific peptides for influenza virus (Flu) melanoma MART-1 (MART), gp100:209–217, or gp100:209–217 (210M). Data from PBL from patients 1 and 2 are the mean values of quadruplicate samples, with SD in parentheses. Control responder cells were CTL line R6C12 and a melanoma-reactive TIL culture from patient 2.